What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review

Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of the disease most relevant to key stakeholders. A systematic r...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia : diagnosis, assessment & disease monitoring assessment & disease monitoring, 2019-12, Vol.11 (1), p.231-247
Main Authors: Tochel, Claire, Smith, Michael, Baldwin, Helen, Gustavsson, Anders, Ly, Amanda, Bexelius, Christin, Nelson, Mia, Bintener, Christophe, Fantoni, Enrico, Garre-Olmo, Josep, Janssen, Olin, Jindra, Christoph, Jørgensen, Isabella F., McKeown, Alex, Öztürk, Buket, Ponjoan, Anna, Potashman, Michele H., Reed, Catherine, Roncancio-Diaz, Emilse, Vos, Stephanie, Sudlow, Cathie
Format: Article
Language:English
Subjects:
Activities of daily living
Alzheimer's Disease
Autonomy
Burden
Caregivers
Diagnostic Assessment & Prognosis
Healthcare professionals
Memory
Mild cognitive impairment
Outcomes
Patients
Qualitative
Quality of life
Quantitative
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of the disease most relevant to key stakeholders. A systematic review sought research that elicited information from people with AD, their caregivers, and health-care professionals on which outcomes of the disease were important. Studies published in any language between 2008 and 2017 were included. Participants in 34 studies described 32 outcomes of AD. These included clinical (memory, mental health), practical (ability to undertake activities of daily living, access to health information), and personal (desire for patient autonomy, maintenance of identity) outcomes of the disease. Evidence elicited directly from the people most affected by AD reveals a range of disease outcomes that are relevant to them but are not commonly captured in clinical trials of new treatments.
ISSN:2352-8729
2352-8729
DOI:10.1016/j.dadm.2018.12.003